Erlotinib. Metastatic cancer of the pancreas: Palliative care is still the best option

Prescrire International

Volumn 17, Issue 93, 2008, Pages 6-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; GEMCITABINE;

ADVANCED CANCER; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG ERUPTION; DRUG INDICATION; DRUG RESPONSE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERSTITIAL PNEUMONIA; METASTASIS; MONOTHERAPY; PANCREAS CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME;

EID: 38849143187     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. European Medicines Agency - CHMP "European Public Assessment Report (EPAR) (rev. 4) - Tarceva. Scientific discussion" 18 pages; posted on the EMEA website on 14 June 2007.
2. Prescrire Rédaction "Adénocarcinomes du pancréas. Des cancers peu sensibles aux médicaments cytotoxiques" Rev Prescrire 2007; 27 (287): 683-686.